Home › Atherosclerosis › New York › The Bronx
Atherosclerosis clinical trials in The Bronx, NY
3 studies for Atherosclerosis are looking for participants at sites in and around The Bronx (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
RecruitingPhase 2
- CHEAR Center LLC, The Bronx
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
RecruitingPhase 2/3
- Albert Einstein College of Medicine - Montefiore Medical Center, The Bronx
- James J Peters VA Medical Center, The Bronx
- Mattoo & Bhat Medical Associates, P.C., College Point · 4 mi away
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
RecruitingPhase 3
- Research Site, The Bronx
About Atherosclerosis
Atherosclerosis is hardening and narrowing of the arteries caused by the buildup of a fatty substance called plaque. Learn about the risks and prevention.
More about Atherosclerosis on MedlinePlus
Atherosclerosis trials in other cities
- Boston, MA10 studies
- Houston, TX10 studies
- Washington, DC9 studies
- Arlington, VA8 studies
- Orlando, FL8 studies
- Hialeah, FL8 studies
- Durham, NC7 studies
- Memphis, TN7 studies
- Miami, FL7 studies
- Dallas, TX7 studies
- Las Vegas, NV7 studies
- Minneapolis, MN6 studies
Other studies in The Bronx
- Non-Small Cell Lung Cancer25 studies
- Breast Cancer17 studies
- Acute Myeloid Leukemia15 studies
- Lung Cancer13 studies
- Cancer (all types)12 studies
- Cardiovascular Disease12 studies
- Prostate Cancer11 studies
- Heart Failure11 studies
- Head and Neck Squamous Cell Carcinoma9 studies
- Colorectal Cancer9 studies
- Metastatic Cancer9 studies
- Asthma9 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.